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Background: To precisely calculate skin dose and thus to evaluate the relationship between the skin dose and
permanent alopecia for pediatric medulloblastoma patients treated with proton beams.
Methods: The dosimetry and alopecia outcomes of 12 children with medulloblastoma (ages 4-15 years) comprise
the study cohort. Permanent alopecia was assessed and graded after completion of the entire therapy. Skin threshold
doses of permanent alopecia were calculated based on the skin dose from the craniospinal irradiation (CSI) plan using
the concept of generalized equivalent uniform dose (gEUD) and accounting for chemotherapy intensity. Monte Carlo
simulations were employed to accurately assess uncertainties due to beam range prediction and secondary particles.
Results: Increasing the dose of the CSI field or the dose given by the boost field to the posterior fossa increased total
skin dose delivered in that region. It was found that permanent alopecia could be correlated with CSI dose with a
threshold of about 21 Gy (relative biological effectiveness, RBE) with high dose chemotherapy and 30 Gy (RBE) with
conventional chemotherapy.
Conclusions: Our results based on 12 patients provide a relationship between the skin dose and permanent alopecia
for pediatric medulloblastoma patients treated with protons. The alopecia risk as assessed with gEUD could be
predicted based on the treatment plan information.
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Medulloblastoma is the most common malignant brain
tumor in children and arises in the posterior fossa.
Current studies show that combined modality therapies
including surgery, chemotherapy and radiation can
achieve a cure in approximately 80% of children with
standard risk disease and in excess of 60% in children with
high risk disease [1]. With increasing long-term survival,
there is a growing concern with treatment-related side
effects. Permanent alopecia can have a profound impact
on a child’s quality of life (QoL), contributing to low self-
esteem and adversely affect psychosocial functioning [2,3].* Correspondence: TYOCK@mgh.harvard.edu
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unless otherwise stated.To mitigate the side effects of photon radiation ther-
apy, various radiation delivery methods have been devel-
oped with an improved conformity of radiation dose
delivery, but these refinements in the photon techniques
still entail significant entrance and exit dose. Compared
with photon techniques, proton radiation affords a high
radiation dose to the target volume while decreasing the
amount of normal tissue irradiated by a factor of 2-3
times [4,5] and a few studies have estimated the benefits
in decreased second tumor rates and long term costs of
caring for children [6]. Ongoing studies document some
of the partially mitigated late effects of neurocognitive
deficits, hearing deficits, and endocrine deficits [7].
The potential risk of permanent alopecia after photon
cranial irradiation in adults has been studied previously
[8]. However, little is known about the differences in
sensitivity to radiation with regards to alopecia outcomes. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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are still developing, children may be more sensitive than
adults to radiation. In addition to the normal tissue tox-
icity and tolerances that adults are subject to, further
growth and development is stunted in children [9].
We made the clinical observation that after 36 Gy(RBE)
and concurrent chemotherapy, hair regrowth in pediatric
patients was often incomplete. A few young patients
treated with intensive or concurrent chemotherapy (be-
yond vincristine) also had some signs of permanent alope-
cia at doses as low as 23.4 Gy(RBE) of proton radiotherapy.
Discussions with clinicians at other centers (not proton
specific) have revealed that this is a widespread problem
especially with the current Children’s Oncology Group
(COG) regimen of daily carboplatin and 36 Gy of CSI in
the high risk study.
Permanent alopecia has been a major source of dissatis-
faction with our patients which was consistent with a find-
ing by Kinehan et al from the Childhood Cancer survival
studies [3]. Permanent alopecia was statistically signifi-
cantly associated with worse QoL scores for the global
status indicator as well as all three subsets of anxiety,
somatization and depression [3]. Therefore, the purpose of
this study is three fold: 1) to determine the threshold CSI
dose causing permanent alopecia in children with medul-
loblastoma, 2) to identify other contributing factors such
as chemotherapy; and 3) to use this data to improve the
proton CSI technique to further decrease skin dose and
thus decrease the risk of permanent alopecia.
Materials and methods
Patient selection and treatment planning
Twelve pediatric patients with medulloblastoma (median
age 6, range 4-15 years) were treated with proton CSI
and boost at Massachusetts General Hospital (MGH)Table 1 Patient characteristics
Case no. Age (y) Gender Prescribed dos
CSI
1 7 F 23.4
2 4 F 23.4
3 5 M 23.4
4 10 M 23.4
5 4 M 23.4
6 4 M 27.0
7 6 M 30.6
8 15 M 36.0
9 9 M 36.0
10 8 F 36.0
11 5 F 36.0
12 4 F 36.0
Abbreviations: Mmale, F female, HD high-dose chemotherapy, CD conventional-dosewhose permanent alopecia outcomes were graded ac-
cording to Common Terminology Criteria for Adverse
Events (CTCAE) v4.0 [10]. For this study only the brain
fields were considered. CSI (whole brain) doses ranged
from 23.4 to 36.0 Gy(RBE). Boost fields consisted of
either whole posterior fossa or tumor bed involved field
and were treated to a total dose of 54 Gy(RBE) except in
case 7 where 50.4 Gy(RBE) was used (Table 1).
In order to accurately assess skin dose, the skin was
manually defined as the volume from the outer surface of
the skin to the depth of about 6-7 mm. If the skin was
thinner than 6 mm, the skin was defined from the outer
surface of the skull to the outer skin surface. The treat-
ment planning system XiO (Computerized Medical Sys-
tem Inc.) was used for all treatment plans. All patients had
completed both chemotherapy and radiation therapy more
than 1.25 years before the follow up alopecia grading to
ensure adequate time for the regrowth of hair.
Monte Carlo simulation
The prescribed brain fields have a proton beam range
equaling the water-equivalent thickness of the patient’s
head. As a range uncertainty safety margin, our institu-
tion typically adds an additional 3.5% + 1 mm to the pre-
scribed range. Thus, for medulloblastoma patients, the
added range to account range uncertainty of the proton
beam in the brain could cause a significant increase in
the skin dose. Each treatment plan was re-calculated
using a Monte Carlo dose calculation system for two
purposes: 1) to avoid potential uncertainties in our
analysis due to dose calculation errors, and 2) to better
define the actual range uncertainty in these particular
cases to determine if the addition 3.5% + 1 mm is truly
necessary. This code considers all the modules in the














chemotherapy, SR standard-risk, and HR high-risk.
Figure 1 Proton dose distribution for a single field as
calculated with (left) the treatment planning system (XiO) and
(right) a Monte Carlo simulation.
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particles. Monte Carlo dose calculations are known to
be more accurate than a pencil-beam algorithm used in
commercial treatment planning systems [11].
Passive scattered proton therapy is associated with a
neutron background. Furthermore, there are short-range
protons from aperture scattering. Both effects are not
modeled in analytical dose calculation algorithms but
could contribute to the skin dose. Monte Carlo simula-
tions allow us to consider all secondary particles gener-
ated in the treatment head. We calculated the skin dose
from secondary particles separately to assess the impact
of neutrons, photons, electrons, and secondary protons.
Neutrons have a high radiation weighting factor while
electrons, photons and secondary protons have a short-
range and thus could potentially increase the skin dose
at the entrance of the beam into the patient.
Grading and dose-response analysis
Permanent alopecia was graded with CTCAE v4.0 and
analyzed based on the generalized equivalent uniform
dose (gEUD) [10,12]. Alopecia grading is as follows: 0 =
none; 1 = hair loss of <50% (a different hair style may be
required); 2 = hair loss of > =50% (a wig or hair piece is
necessary). To assess the skin dose in which the hair fol-
licles are found, the cumulative dose-volume histograms
(DVHs) were obtained from the manually contoured
skin volume in the XiO treatment planning system.












Here, Di is the dose in the i’th voxel, N is the number
of voxels in the anatomic structure of interest, and ‘a’ is
the tumor or normal tissue-specific parameter (we as-
sume a = 10 for skin) that describes the dose-volume
effect [13]. To investigate the relationship between the
alopecia grade and the skin dose, gEUDs for the CSI
fields and boost fields were separately calculated and
analyzed. Chemotherapy intensity and its effects on
permanent alopecia were also considered.
Results
Dose calculation uncertainties when analyzing skin dose
On average, the depth of the scalp follicle is located ap-
proximately 4.5 mm from the skin surface in adults and
somewhat shallower in younger children, i.e. pediatric
scalp skin is somewhat thinner than adult skin. Assum-
ing that the scalp skin is thin and the dose distribution
in it is uniform, the average dose of the scalp skin equals
the follicle dose.To verify that the range of the proton beam and the
following skin dose calculated based on the treatment
planning system is correctly predicted, Monte Carlo (MC)
simulations were performed. One example is shown in
Figure 1 where a beam of 167-mm range was delivered to
the patient through the patient-field-specific aperture and
compensator. The difference of the average beam range
was less than 1.0 mm with root-mean-square-errors of
2.6 mm between XiO and MC simulation resulting in a
similar gEUD for the skin dose of 1.73 and 1.70 Gy(RBE),
respectively (for 1.8 Gy(RBE) of the prescribed CSI dose).
Note that for the comparison purpose only one faction
was considered, but the total dose was 54 Gy(RBE). The
comparisons between XiO and MC calculations for the
other 11 patients treated with field ranges of 151-172 mm
were similar.
The proton beams were delivered with a posterior
oblique field with a prescription dose as shown in Table 1.
The doses include a relative biological effectiveness (RBE)
of 1.1, 1 and 10 for protons, electrons and neutrons, re-
spectively. The RBE could potentially be slightly higher in
the distal part of the SOBP. This is clinically not consid-
ered due to uncertainties in tissue, dose and LET (liner
energy transfer) dependency of RBE values. The MC simu-
lated dose distributions are based on primary protons as
well as secondary particles generated by proton-induced
nuclear interactions in the treatment head. Even though
the number of neutrons was about 14% of the primary pro-
tons, most of them passed the patient without any interac-
tions because of the low interaction cross-section and thus
the skin dose was not appreciably increased. Overall, the
skin dose due to all secondary particles was less than 1% of
the proton dose.
Skin dose and grade
Despite some patient-to-patient variability, the DVHs of the
12 patients treated with standard CSI and boost treatment
show similar patterns (Figure 2). Approximately >70% of
the CSI prescription dose was delivered to >50% of the skin
volume, and the boost treatment sharply increased the dose
Figure 2 Dose volume histograms of 12 patients treated with
CSI and boost plan along with assigned alopecia grades.
Figure 3 The gEUD values for 12 patients treated with CSI fields
with assigned alopecia grades (boost volume was excluded from
the gEUD analysis). Those patients who also received HD
chemotherapy are indicated by circles.
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the whole scalp was used and correlated with the CTCAE
v4.0 grade.
Figure 3 shows the gEUD values with CSI treatment
and alopecia grades for the 12 patients. Our results dem-
onstrate that the scalp dose from the CSI field correlates
well with alopecia outcomes. However, other factors,
such as chemotherapy intensity also play a role. All
patients in the current cohort assigned to the high-risk
group and treated with > 27.0 Gy(RBE) showed alopecia
of grade 1 or 2, while no alopecia was observed with 3
patients (case 1, 2, and 4) out of 5 patients in the
standard-risk (lower CSI dose) group. Of the 12 patients,
5 patients (case 3, 5, 6, 7, and 12) were treated with high
dose (HD) chemotherapy, and all of them showed per-
manent alopecia of grade 1 or 2, even though two
patients (case 3 and 5) had low skin doses of 21.3 and
22.2 Gy(RBE), respectively. Patients getting lower CSI
doses (<23.4 Gy(RBE) seemed to have no alopecia, un-
less given HD chemotherapy. HD chemotherapy is asso-
ciated with permanent alopecia in pediatric patients with
a skin doses ranges of 21.0 - 34.2 Gy(RBE).
As one might expect, if the skin dose in the posterior
fossa region that receives dose from the boost plan is in-
cluded in the gEUD analysis, the correlation of prescrip-
tion dose and alopecia is inconsistent. For example, in
the cases of patients 5 and 6, both treated with a similar
prescribed boost dose of 30.6 and 27.0 Gy(RBE) as
shown in Figure 4, respectively, the gEUD values in the
skin were about 13.9 and 32.0 Gy(RBE), respectively.
Case 5 was treated with an involved field technique,
which includes just the primary tumor bed plus a 1.5 cm
margin for CTV. However, case 6 includes the whole
posterior fossa in the boost. Therefore, the target volumefor case 6 was both more superficial and much larger
(>3 times) than for case 5. Area dependent grading
would be required to consider the boost region separ-
ately. Clearly though, the larger and more superficial the
posterior fossa boost volume is, the higher the dose to
the skin in this region.
We show, for example, one patient with permanent
CTC grade 2 alopecia over most of his scalp sparing only
the hair in a strip at the vertex of his head. The vertex hair
regrowth was in the area of skin that received 30 Gy(RBE)
or less (Figure 5). These findings indicate reduction of
range and modulation (using compensators) can reduce
skin dose from proton therapy partially mitigating the risk
of permanent alopecia.
Discussion
To understand the dose dependence of radiation-induced
alopecia, a numerical method has been used in calculating
the local skin dose in the skin depth (e.g. 4-5 mm) at each
region of interest [8]. However, our study showed that skin
dose could be rationally assessed using gEUD based on
DVHs obtained from the treatment planning system for
the CTCAE-based alopecia grading. This is a very simple
but powerful method in assisting the oncologist, physicist,
and dosimetrist to predict potential alopecia risk during
treatment planning in the CSI portion of treatment for
medulloblastoma.
Based on a gEUD analysis, it was suggested that a mean
dose of ~21 Gy(RBE) could be considered as the threshold
for permanent alopecia for pediatric patients treated with
high dose chemotherapy, but the alopecia threshold dose
may be higher, 30 Gy(RBE) with conventional chemother-
apy. This relationship excludes the boost dose in the cal-
culation. With the limited number of cases in our study,
Figure 4 Proton dose distributions of the patient 5 (left) and 6 (right) treated with CSI and boost field.
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are notably different compared to the adult study correlat-
ing radiation dose to permanent alopecia [8]. They esti-
mated that 43.0 Gy to the skin causes permanent alopecia
in 50% of adult patients.
Previous studies had demonstrated a clear advantage of
proton beams in a dosimetric comparison with conven-
tional X-ray and intensity-modulated photon therapy
(IMPT), particularly in the posterior fossa and spinal col-
umn in children with medulloblastoma [5,7]. However, for
cranial irradiation proton radiation does not show a skin
sparing advantage over photons. This is mainly due to the
added range uncertainty margin of 3.5% of the prescribed
range + 1 mm. This caused the exit skin dose to be as high
as ~80% + of the prescribed target dose. Thus, eliminating
the 3 mm margin added for the uncertainty of the dose
calculation algorithm effectively reduces skin dose and has
been undertaken at our institution in the higher CSI dose
patients. Permanent alopecia outcomes using this im-
proved technique are still immature as of the date of
submission of this manuscript as many patients are still
receiving chemotherapy or not sufficiently far from
therapy to securely assess permanent alopecia.Figure 5 Planned dose distribution of CSI field (left) with frontal (midThe boost delivers additional dose to the skin in the
posterior fossa region and it has potential to affect the
CTCAE-based alopecia grading as seen for cases 5 and
6. It is required to define the area-dependent alopecia
grading to quantitatively determine the effects of the
boost fields. The CTCAE-based grading only supports
the gross alopecia grading over the scalp skin. Assessing
the relationship between the dose in the microscopic
area and their alopecia grade may offer the better under-
standing for the potential of alopecia with the radiation
therapy. The volume of the medulloblastoma boost field
(tumor bed involved field versus whole posterior fossa)
is a study question in the latest COG (Children’s Oncol-
ogy Group) trial. The study should definitively answer
the question whether the larger field is ultimately needed
for disease control. However, clearly, the smaller tumor
bed involved field boost treats on average less skin
(presented above) and less normal brain [14].
Conclusion
Skin dose could be correlated with permanent alopecia
as well as the use of intensive chemotherapy. Our study
using Monte Carlo dose calculation show that skin dosedle) and left lateral views (right) of Case 8.
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obtained from the treatment planning system for alopecia
grading.
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